Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma

Thyroid

Volumn 23, Issue 3, 2013, Pages 294-300

  Frank Raue, Karin ^a   Machens, Andreas ^b   Leidig Bruckner, Gudrun ^a   Rondot, Susanne ^a   Haag, Christine ^a   Schulze, Egbert ^a   Lorenz, Angela ^a   Kreissl, Michael C ^c   Dralle, Henning ^b   Raue, Friedhelm ^a   Schmid, Kurt W ^d  

^a Endocrine Practice   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN RET;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONSECRETORY THYROID MEDULLARY CARCINOMA; PREVALENCE; PRIORITY JOURNAL; SPORADIC THYROID MEDULLARY CARCINOMA; THYROID MEDULLARY CARCINOMA;

AGED; CARCINOMA, MEDULLARY; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874843098     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0236     Document Type: Article

References (33)

1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. 2009 Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612
2. Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P, Modigliani E 2000 Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 85:919-922
3. Machens A, Dralle H 2010 Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655-2663
4. Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M 2008 Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158: 239-246
5. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S 2007 Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450-455
6. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084
7. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163-168
8. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hufner M, Niederle B, Brabant G 2004 Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52-58
9. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
10. Mendelsohn G, Wells SA Jr., Baylin SB 1984 Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 54:657-662
11. Harach HR, Wilander E, Grimelius L, Bergholm U, Westermark P, Falkmer S 1992 Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma. Pathol Res Pract 188:123-130
12. Schmid KW, Ensinger C 1998 ''Atypical'' medullary thyroid carcinoma with little or no calcitonin expression. Virchows Arch 433:209-215
13. Diez JJ, Iglesias P 2004 Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 14:984-985
14. Redding AH, Levine SN, Fowler MR 2000 Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 10:919-922
15. Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid KW, Broelsch CE 2004 Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 14:468-470
16. Sand M, Gelos M, Sand D, Bechara FG, Bonhag G, Welsing E, Mann B 2006 Serum calcitonin negative medullary thyroid carcinoma. World J Surg Oncol 4:97
17. Dora JM, Canalli MH, Capp C, Punales MK, Vieira JG, Maia AL 2008 Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: Case report and review of the literature. Thyroid 18:895-899
18. Wang TS, Ocal IT, Sosa JA, Cox H, Roman S 2008 Medullary thyroid carcinoma without marked elevation of calcitonin: A diagnostic and surveillance dilemma. Thyroid 18:889-894
19. Giovanella L, Crippa S, Cariani L 2008 Serum calcitoninnegative medullary thyroid carcinoma: Role of CgA and CEA as complementary markers. Int J Biol Markers 23:129-131
20. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG 2011 Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39:148-152
21. Raue F 1998 German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary thyroid carcinoma/multiple endocrine neoplasia type 2. Langenbecks Arch Surg 383:334-336
22. Machens A, Lorenz K, Dralle H 2009 Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: Value of pretherapeutic calcitonin levels. Ann Surg 250:305-310
23. Machens A, Frank-Raue K, Lorenz K, Rondot S, Raue F, Dralle H 2012 Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin Endocrinol (Oxf) 76:691-697
24. Frank-Raue K, Rondot S, Hoeppner W, Goretzki P, Raue F, Meng W 2005 Coincidence of multiple endocrine neoplasia types 1 and 2: Mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. J Clin Endocrinol Metab 90:4063-4067
25. Edge SB, ByrdDR, Compton CC, Fritz AG,Greene FL, Trotti A (eds) 2010 AJCC Cancer Staging Manual, 7th ed. Springer-Verlag, New York.
26. Krisch K, Krisch I, Horvat G, Neuhold N, Ulrich W 1985 The value of immunohistochemistry in medullary thyroid carcinoma: A systematic study of 30 cases. Histopathology 9:1077-1089
27. Matias-Guiu X, LaGuette J, Puras-Gil AM, Rosai J 1997 Metastatic neuroendocrine tumors to the thyroid gland mimicking medullary carcinoma: A pathologic and immunohistochemical study of six cases. Am J Surg Pathol 21: 754-762
28. Leboulleux S, Baudin E, Young J, Caillou B, Lazar V, Pellegriti G, Ducreux M, Schaison G, Schlumberger M 1999 Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: Differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140:187-191
29. Inzerillo AM, Zaidi M, Huang CL 2002 Calcitonin: The other thyroid hormone. Thyroid 12:791-798
30. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M, Raue F 2001 Prognostic value of codon 918 (ATG - > ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66
31. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 93:682-687
32. Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME, Opocher G 2011 Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: A useful tool for patient risk stratification. Eur J Endocrinol 164:971-976
33. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E 1984 Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278-285